MP Begins Enrollment in Phase 1/2 Combi. Study of MM-121 & Tarceva in Pat. w/ NSCLC
Posted 02-22-2010 at 06:29 PM by admin
Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
MM-121, Merrimack’s lead oncology therapeutic candidate, is an antibody designed to block signaling of ErbB3. This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.
Cambridge, Mass. (PRWEB) February 22, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva® (erlotinib) in patients with non-small cell lung cancer (NSCLC). This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.
MM-121, Merrimack’s lead oncology therapeutic candidate, is an antibody designed to block signaling of ErbB3. Erlotinib is a small molecule targeting the epidermal growth factor receptor (EGFR).
“Our Network Biology analysis of cancer cells indicates that tumors often become resistant to EGFR-targeted therapies by compensating for tumor growth restriction through the ErbB3 receptor,” stated Clet Niyikiza, Ph.D., Senior Vice President of Development at Merrimack. “We believe that this discovery, which has since been confirmed by leading academic laboratories, indicates that MM-121 in combination with Tarceva® could be a powerful treatment for lung cancer patients who no longer respond to EGFR treatment alone.”
The Phase 1/2 study will initially evaluate the human safety and pharmacokinetics (PK) of MM-121 in combination with erlotinib, establish a safe combination regimen, and then investigate the regimen’s efficacy in the NSCLC patient population. Enrollment of the trial is underway at Horizon Oncology Center in Indiana. Several additional sites are expected to participate in the Phase 1/2 trial.
MM-121 is a monoclonal antibody designed to block signaling of the ErbB3 receptor. ErbB3 is a member of the ErbB family consisting of 4 different receptors, EGFR (aka ErbB1), ErbB2 (Her2), ErbB3 (Her3) and ErbB4 (Her4). These receptors play a critical role in cancer signaling. MM-121 was the first engineered antibody that emerged from Merrimack’s Network Biology platform as well as the first selective ErbB3 antagonist to enter human clinical development. A Phase 1 dose escalation trial testing the safety and pharmacokinetics of MM-121 is ongoing at three sites in the US. Preclinical data exhibiting MM-121s impact on multiple cancer models, including the combination with eroltinib, were presented at the annual meeting of the American Association for Cancer Research and the World Lung Cancer Conference in 2009.
Read the rest of the article here.
© Copyright 1997-2010, Vocus PRW Holdings, LLC.
MM-121, Merrimack’s lead oncology therapeutic candidate, is an antibody designed to block signaling of ErbB3. This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.
Cambridge, Mass. (PRWEB) February 22, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva® (erlotinib) in patients with non-small cell lung cancer (NSCLC). This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.
MM-121, Merrimack’s lead oncology therapeutic candidate, is an antibody designed to block signaling of ErbB3. Erlotinib is a small molecule targeting the epidermal growth factor receptor (EGFR).
“Our Network Biology analysis of cancer cells indicates that tumors often become resistant to EGFR-targeted therapies by compensating for tumor growth restriction through the ErbB3 receptor,” stated Clet Niyikiza, Ph.D., Senior Vice President of Development at Merrimack. “We believe that this discovery, which has since been confirmed by leading academic laboratories, indicates that MM-121 in combination with Tarceva® could be a powerful treatment for lung cancer patients who no longer respond to EGFR treatment alone.”
The Phase 1/2 study will initially evaluate the human safety and pharmacokinetics (PK) of MM-121 in combination with erlotinib, establish a safe combination regimen, and then investigate the regimen’s efficacy in the NSCLC patient population. Enrollment of the trial is underway at Horizon Oncology Center in Indiana. Several additional sites are expected to participate in the Phase 1/2 trial.
MM-121 is a monoclonal antibody designed to block signaling of the ErbB3 receptor. ErbB3 is a member of the ErbB family consisting of 4 different receptors, EGFR (aka ErbB1), ErbB2 (Her2), ErbB3 (Her3) and ErbB4 (Her4). These receptors play a critical role in cancer signaling. MM-121 was the first engineered antibody that emerged from Merrimack’s Network Biology platform as well as the first selective ErbB3 antagonist to enter human clinical development. A Phase 1 dose escalation trial testing the safety and pharmacokinetics of MM-121 is ongoing at three sites in the US. Preclinical data exhibiting MM-121s impact on multiple cancer models, including the combination with eroltinib, were presented at the annual meeting of the American Association for Cancer Research and the World Lung Cancer Conference in 2009.
Read the rest of the article here.
© Copyright 1997-2010, Vocus PRW Holdings, LLC.
Total Comments 0
Comments
Recent Blog Entries by admin
- Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand (07-29-2010)
- Potential Biomarkers of VELCADE Activity in Patients w/Relapsed Mantle Cell Lymphoma (07-29-2010)
- UT Health Science Center team finds adrenal cancer gene (07-29-2010)
- £50m boost to help cancer patients (07-29-2010)
- Generic Gemzar may appear soon (07-29-2010)
